POSTERS ESMO 2024

Cáncer urotelial

RUTIVAC-1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals with High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG.

RUTIVAC-1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals with High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG.

Poster Bd #: 1971P

Poster

Descargar poster

Autor
Pol Servian

Hospital Universitario Hermanos Trias y Pujol. Badalona

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON